FHTX Quote, Financials, Valuation and Earnings

Moderna has a net margin of -244.9% compared to Foghorn Therapeutics's net margin of 0.7%. Foghorn Therapeutics's return on equity of -- beat Moderna's return on equity of -17.44%.

Foghorn Therapeutics has a consensus price target of $12.50, signalling upside risk potential of 150%. On the other hand Moderna has an analysts' consensus of $74.19 which suggests that it could grow by 75.88%. Given that Foghorn Therapeutics has higher upside potential than Moderna, analysts believe Foghorn Therapeutics is more attractive than Moderna.

Foghorn Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Foghorn Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Foghorn Therapeutics quarterly revenues are $7.8M, which are smaller than Moderna quarterly revenues of $1.9B. Foghorn Therapeutics's net income of -$19.1M is lower than Moderna's net income of $13M. Notably, Foghorn Therapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics is 9.35x versus 3.23x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Omega Therapeutics has a net margin of -244.9% compared to Foghorn Therapeutics's net margin of -629.56%. Foghorn Therapeutics's return on equity of -- beat Omega Therapeutics's return on equity of -171.4%.

Foghorn Therapeutics has a consensus price target of $12.50, signalling upside risk potential of 150%. On the other hand Omega Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1030.95%. Given that Omega Therapeutics has higher upside potential than Foghorn Therapeutics, analysts believe Omega Therapeutics is more attractive than Foghorn Therapeutics.

Foghorn Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omega Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Foghorn Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omega Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics pays -- of its earnings as a dividend. Omega Therapeutics pays out -- of its earnings as a dividend.

Foghorn Therapeutics quarterly revenues are $7.8M, which are larger than Omega Therapeutics quarterly revenues of $2.6M. Foghorn Therapeutics's net income of -$19.1M is lower than Omega Therapeutics's net income of -$16.4M. Notably, Foghorn Therapeutics's price-to-earnings ratio is -- while Omega Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics is 9.35x versus 5.72x for Omega Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PureTech Health PLC has a net margin of -244.9% compared to Foghorn Therapeutics's net margin of --. Foghorn Therapeutics's return on equity of -- beat PureTech Health PLC's return on equity of --.

Foghorn Therapeutics has a consensus price target of $12.50, signalling upside risk potential of 150%. On the other hand PureTech Health PLC has an analysts' consensus of $53.25 which suggests that it could grow by 183.25%. Given that PureTech Health PLC has higher upside potential than Foghorn Therapeutics, analysts believe PureTech Health PLC is more attractive than Foghorn Therapeutics.

Foghorn Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PureTech Health PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Foghorn Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PureTech Health PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics pays -- of its earnings as a dividend. PureTech Health PLC pays out -- of its earnings as a dividend.

Foghorn Therapeutics quarterly revenues are $7.8M, which are larger than PureTech Health PLC quarterly revenues of --. Foghorn Therapeutics's net income of -$19.1M is higher than PureTech Health PLC's net income of --. Notably, Foghorn Therapeutics's price-to-earnings ratio is -- while PureTech Health PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics is 9.35x versus 300.98x for PureTech Health PLC. Usually stocks with elevated PS ratios are considered overvalued.

Sana Biotechnology has a net margin of -244.9% compared to Foghorn Therapeutics's net margin of --. Foghorn Therapeutics's return on equity of -- beat Sana Biotechnology's return on equity of --.

Foghorn Therapeutics has a consensus price target of $12.50, signalling upside risk potential of 150%. On the other hand Sana Biotechnology has an analysts' consensus of $9.40 which suggests that it could grow by 449.71%. Given that Sana Biotechnology has higher upside potential than Foghorn Therapeutics, analysts believe Sana Biotechnology is more attractive than Foghorn Therapeutics.

Foghorn Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sana Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Foghorn Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sana Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics pays -- of its earnings as a dividend. Sana Biotechnology pays out -- of its earnings as a dividend.

Foghorn Therapeutics quarterly revenues are $7.8M, which are larger than Sana Biotechnology quarterly revenues of --. Foghorn Therapeutics's net income of -$19.1M is higher than Sana Biotechnology's net income of -$59.9M. Notably, Foghorn Therapeutics's price-to-earnings ratio is -- while Sana Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics is 9.35x versus -- for Sana Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.